2024
Considerations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings
Kelly A, Bahlke M, Baker J, de Beaufort C, Belin R, Fonseca H, Hale P, Holm J, Hsia D, Jastreboff A, Juliusson P, Murphy M, Pak J, Paul E, Rudolph B, Srivastava G, Tornøe C, Weghuber D, Fox C. Considerations for the design and conduct of pediatric obesity pharmacotherapy clinical trials: Proceedings of expert roundtable meetings. Pediatric Obesity 2024, 19: e13161. PMID: 39289849, DOI: 10.1111/ijpo.13161.Peer-Reviewed Original ResearchAnti-obesity medicationsExcessive weight reductionClinical trialsEnd pointsDown-titrationEligibility criteriaLong-term health outcomesBMI z-scoreActive comparatorEfficacy end pointPlacebo-controlled trialSecondary end pointsRun-in phaseFollow-up periodFollow-up phaseHealth outcomesObesity expertsTrial eligibility criteriaClinical careWeight reductionMultidisciplinary groupClinical trial protocolsPrimary outcomeWeight regainTrial protocol
2012
Year in Diabetes 2012: The Diabetes Tsunami
Sherwin R, Jastreboff AM. Year in Diabetes 2012: The Diabetes Tsunami. The Journal Of Clinical Endocrinology & Metabolism 2012, 97: 4293-4301. PMID: 23185035, PMCID: PMC3513534, DOI: 10.1210/jc.2012-3487.BooksConceptsClinical trialsAmerican Diabetes Association/European AssociationNew-onset type 1 diabetesPrevalence of diabetesCurrent treatment optionsLarge clinical trialsRecent clinical trialsBenefits of exerciseDevelopment of obesityNormal glucose metabolismType 1 diabetesStudy of DiabetesΒ-cell functionNovel therapeutic targetCentral nervous systemObese childrenSignificant morbidityTreatment optionsEndocrine SocietyInpatient settingTreatment strategiesIndividualized careOptimal preventionGlucose metabolismOptimization of interventions